Reverse Proteomics Research
Institute, Co., Ltd.
REPRORI was founded in May 2001 by joint collaboration of Ajinomoto Co., Inc., Astellas Pharma Inc., Sumitomo Chemical Co.,Ltd, Dainippon Sumitomo Pharma Co., Ltd., Chugai Pharmaceutical Co., Ltd., Teijin Pharma Ltd, Nippon Shinyaku Co., Ltd., Hitachi Chemical Co., Ltd., Hitachi, Ltd., and Mochida Pharmaceutical Co., Ltd. It was later joined by Nippon Kayaku Co., Ltd.
Its purpose is to obtain the knowledge base for generation of new drugs that would satisfy unmet medical needs by studying the interactions between commonly used small molecule drugs and human proteins prepared from corresponding full length cDNAs. These cDNAs are selected from human cDNAs that have been accumulated by Helix Research Institute (Kisarazu, Japan), Institute of Medical Sciences, University of Tokyo, and REPRORI.
REPRORI received its research funds from the Ministry of Economy, Trade and Industry through the New Energy and Industrial Technology Development Organization as well as from the participating companies.
We are focusing on the development of the analytical methods, including size exclusion chromatography, immobilization methods of proteins or compounds and certain chips for Biacore method, of interaction between proteins and? drugs. Moreover, we are trying to obtain human cDNAs and the variant cDNAs by variations of splicing and transcription start sites of mRNAs.
Address: Yamamoto Bldg., 1-7-12 Kaji-cho, Chiyoda-ku,
Tokyo 101-0044, Japan
Jun. 25, 2008